Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

adagrasib

(a-dah-GRA-sib)
A drug used alone or with cetuximab to treat adults with colorectal cancer or non-small cell lung cancer that has spread and has a certain mutation (change) in the KRAS gene. It is used in patients whose cancer was treated with other systemic therapy. It is also being studied in the treatment of other types of cancer. Adagrasib blocks a protein (KRAS G12C) made by the mutated KRAS gene, which may help keep cancer cells from growing and may kill them. It is a type of targeted therapy. Also called Krazati.
More Information
Search NCI's Dictionary of Cancer Terms